T1DM Therapeutics in Major Developed Markets Forecast to Year 2021 3 | Page 5

4.4.2 Clinical Trial Duration 74
4.4.3 Clinical Trial Size 78
4.4.4 Comparative Clinical Trial Metrics Analysis 82
4.5 Promising Pipeline Molecules 84
4.5.1 Insulin Therapies 84
4.5.2 Non-insulin Adjuvant Therapies 89
5 Market Forecast to 2021 99
5.1 Geographical Markets 99
5.2 Global Markets 99
5.3 North America 102
5.3.1 Treatment Usage Patterns 102
5.3.2 Annual Cost of Therapy 104
5.3.3 Market Size 106
5.4 Top Five European Markets 108
5.4.1 Treatment Usage Patterns 108
5.4.2 Annual Cost of Therapy 109
5.4.3 Market Size 111
5.5 Japan 113
5.5.1 Treatment Usage Patterns 113
5.5.2 Annual Cost of Therapy 114
5.5.3 Market Size 114
5.6 Drivers and Barriers for the T1DM Therapeutics Market 115
5.6.1 Drivers 115
5.6.2 Barriers 117
6 Strategic Consolidations 119